Advances in Cancer Research
Regular price
64.750 KD
inc. VAT
Couldn't load pickup availability
Table of contents
- Contentsv
- Contributors to Volume 98ix
- Foundations in Cancer Research1
- Chapter 1: Why Do We Not All Die of Cancer at an Early Age?1
- I. Introduction2
- II. Immune Surveillance2
- III. Genetic Surveillance (DNA Repair)3
- IV. Intracellular Surveillance4
- V. Is There Epigenetic Surveillance?6
- VI. Intercellular Surveillance7
- VII. Summary14
- Acknowledgments14
- References14
- Foundations in Cancer Research17
- Chapter 2: The Early History of Plasma Cell Tumors in Mice, 1954-197617
- I. Introduction18
- II. Plasma Cells Before the 1950s: Discovery, Uncertain Origins18
- III. Multiple Myeloma19
- IV. Abnormal Protein20
- V. New Ideas About the Cellular Basis of Antibody Formation in the 1950s20
- VI. First PCTs in Mice22
- VII. Lloyd Law's Suggestion23
- VIII. X5563 and X564725
- IX. Specific Induction of PCTs in Mice by Implanting Millipore Diffusion Chambers: Ruth Merwin and T26
- X. Mineral Oil and the Hyperimmunization Hypothesis28
- XI. Discoveries on Antibody Structure Using Human Myeloma Proteins Changed the Course of Immunology,31
- XII. Enter Mel Cohn33
- XIII. Pneumococcal Type C Polysaccharide (PnC) and Phosphorylcholine34
- XIV. Herman Eisen, DNP, and MOPC31538
- XV. Irrelevant and Relevant Antigens39
- XVI. The Antidextrans, Antilevans, and Antigalactans41
- XVII. Growing PCTs in Culture and Growth Factors45
- Acknowledgments47
- References47
- Foundations in Cancer Research53
- Chapter 3: Mouse Mammary Tumor Biology: A Short History53
- Abbreviations54
- I. Introduction54
- II. The Dawning of Experimental Cancer Research57
- A. The Origins of the Laboratory Mouse57
- B. The First Mouse Mammary Tumors58
- C. Spontaneous and Transplanted Tumors 1890-191159
- III. Mendelian Mouse Genetics: 1909-192063
- IV. The Inbred Mouse in Mouse Mammary Tumorigenesis: 1920-193064
- V. The Extrachromosomal Factor: 1933-194065
- VI. The Milk Agent 1936-197067
- A. Filterable Agent67
- B. Electron Microscopy68
- C. Infectivity Assays69
- D. The Natural History of Virus Infections71
- VII. MMTV and the Rise of Tumor Immunology73
- VIII. Hormones and the Emergence of Endocrinology74
- IX. The National Cancer Institute and the Birth of Molecular Biology: 1970-198078
- A. Schools of Mouse Mammary Tumor Biology78
- B. The Emergence of Molecular Biology79
- C. The Search for a Human Breast Cancer Virus82
- D. MMTV and Molecular Oncology83
- X. Neoplastic Progression: 195485
- XI. Neoplastic Progression: 1959 the HAN87
- A. The HAN87
- B. The Test-by-Transplantation89
- C. Comparative Pathology of Preneoplasia90
- D. Tumor Clonality91
- E. Developmental Biology and Neoplastic Progression: Mammary Stem Cells92
- XII. Genetically Engineered Mice: 1984-200693
- A. Genetically Engineered Mice93
- B. Comparative Pathology of Breast Cancer96
- C. "Validation" of Mouse Models97
- D. Biotechnology and the Commercialization of Science99
- XIII. Epilog100
- Acknowledgments101
- References101
- Foundations in Cancer Research117
- Chapter 4: Ordered Heterogeneity and its Decline in Cancer and Aging117
- Abbreviations118
- I. Introduction118
- II. The Role of Tissue Size in Developmental Biology119
- III. Behavior of Dissociated Cells and Their Reassociation121
- IV. The Molecular Basis of Cell-Cell Adhesion122
- V. Contact Relations Among Homophilic Cells in Regulation of Growth and Proliferation126
- VI. Role of the Plasma Membrane in the Regulation of Cell Growth127
- VII. Normalization of Neoplastic Cells by Contact with Normal Cells129
- A. Carcinogenic Initiation of Epidermal Cells and Its Suppression by Adjacent Cells130
- B. Suppression of Solitary Hepatocarcinoma Cells by Intact Liver132
- C. Regional Loss of Ordering Capacity by Carcinogenic Treatment137
- D. Cellular Heterogeneity in Cancer138
- VIII. Concluding Remarks139
- Acknowledgments141
- References141
- Chapter 5: Reversal of Tumor Resistance to Apoptotic Stimuli by Alteration of Membrane Fluidity: The149
- I. Introduction150
- A. General150
- B. From "Structureless Bilayers" to Multicomponent Systems151
- II. Membrane Structure and Dynamics151
- A. Basic Structure151
- B. Membrane Mobility154
- C. Advanced Membrane Formations154
- III. Involvement of Physicochemical Properties of the Plasma Membrane in Cellular Functions of Norma155
- A. Membrane Fluidity155
- B. Monitoring Membrane Fluidity156
- IV. Membrane Fluidity and Apoptosis156
- V. Membrane Fluidity and Cancer159
- A. Membrane Fluidity in Normal and Cancer Cells159
- B. Membrane Fluidity and Cell Cycle160
- C. Fluidity and Metastasis161
- VI. Membrane Fluidity in Cancer Therapy161
- A. Immune-Induced Cell Death161
- B. Radiation-Induced Cell Death162
- C. Chemotherapeutic-Induced Cell Death164
- VII. Modulation of Multidrug Resistance by Alterations of Membrane Fluidity164
- A. Mechanisms of Drug Resistance Related to Membrane Events165
- B. Reversal of MDR by Membrane Fluidity Modulators168
- C. Mechanisms of Apoptosis Induction Related to Plasma Membrane Fluidity Alterations169
- D. Role of Intracellular Membranes in Apoptosis Induction by Apoptotic Inducers173
- VIII. Therapeutic Interventions and Novel Approaches in Cancer Therapy175
- IX. Concluding Remarks179
- Acknowledgments180
- References180
- Chapter 6: Mutant Transcription Factors and Tyrosine Kinases as Therapeutic Targets for Leukemias: F191
- I. Introduction192
- II. PML-RARalpha as a Therapeutic Target for Differentiation Therapy193
- A. Retinoids: Differentiation Therapy in Promye locytic Leukemia193
- B. Arsenic: Induction of Partial Differentiation and Apoptosis in Promyelocytic Leukemia Cells195
- C. Combining ATRA and Arsenic: A Cure for APL?198
- III. Tyrosine Kinases as Target for Apoptosis Induction Therapy200
- A. Selective Inhibition of BCR-ABL as a Model in Targeting Aberrant Tyrosine Kinase200
- B. PDGFR as a Therapeutic Target204
- C. C-KIT as a Therapeutic Target205
- D. FLT-3 as a Therapeutic Target206
- E. FGFR as a Therapeutic Target207
- F. JAK2 as a Therapeutic Target208
- G. Other Potential Benefits of Targeting Tyrosine Kinase Downstream Pathway209
- IV. Perspectives210
- Acknowledgments211
- References211
- Chapter 7: The Effect of Cell-Matrix Interactions and Aging on the Malignant Process221
- I. Introduction222
- II. The Extracellular Matrix223
- III. Age-Dependent Changes of Tissues225
- IV. Cell-Matrix Interactions227
- V. Role of Proteolytic Enzymes and ROS230
- VI. The Elastin-Laminin Receptor233
- VII. Modifications of ECM-P atterning by the Neoplastic Process235
- VIII. Role of ECM Macromolecules238
- IX. Effect of Cell-Aging and of Modified Cell-Matrix Interactions on the Malignant Process241
- X. Signaling by ECM Macromolecules and Their Proteolytic Fragments244
- XI. Concluding Remarks249
- Note Added in Proof250
- Acknowledgments250
- References251
- Index261
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. A very special event the Nobel Minisymposium, “Molecular Oncology – From Bench to Bedside, held at the Karolinska Instituet, in Stockholm, Sweden, was marked the celebration of George and Eva Klein’s combined 160th birthday. To honor this occasion, this 2nd of two volumes brings together contributions by their former students, colleagues and collaborators of the past fifty years into a volume of Advances in Cancer Research dedicated to George and Eva. Over a decade ago, a subdivision of ACR called “Foundations in Cancer Research was initiated and the tributes honoring the Kleins’ bodies of work presented at the minisymposium are especially appropriate for the series.